IL115156A - Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines - Google Patents

Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines

Info

Publication number
IL115156A
IL115156A IL11515695A IL11515695A IL115156A IL 115156 A IL115156 A IL 115156A IL 11515695 A IL11515695 A IL 11515695A IL 11515695 A IL11515695 A IL 11515695A IL 115156 A IL115156 A IL 115156A
Authority
IL
Israel
Prior art keywords
cytosines
dioxolan
hydroxymethyl
cancer
treatment
Prior art date
Application number
IL11515695A
Other languages
English (en)
Other versions
IL115156A0 (en
Original Assignee
Univ Georgia
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia, Univ Yale filed Critical Univ Georgia
Publication of IL115156A0 publication Critical patent/IL115156A0/xx
Publication of IL115156A publication Critical patent/IL115156A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL11515695A 1994-09-06 1995-09-04 Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines IL115156A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17

Publications (2)

Publication Number Publication Date
IL115156A0 IL115156A0 (en) 1995-12-31
IL115156A true IL115156A (en) 2000-07-16

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11515695A IL115156A (en) 1994-09-06 1995-09-04 Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines

Country Status (31)

Country Link
US (3) US6063787A (hu)
EP (2) EP1468687A1 (hu)
JP (1) JP3979662B2 (hu)
KR (1) KR100374477B1 (hu)
CN (3) CN1111409C (hu)
AP (1) AP783A (hu)
AT (1) ATE267015T1 (hu)
AU (1) AU704977B2 (hu)
BG (1) BG63122B1 (hu)
BR (1) BR9508886A (hu)
CA (1) CA2199117C (hu)
CZ (1) CZ297873B6 (hu)
DE (1) DE69533066T2 (hu)
DK (1) DK0781136T3 (hu)
ES (1) ES2219666T3 (hu)
FI (1) FI970918A (hu)
HU (1) HUT77172A (hu)
IL (1) IL115156A (hu)
IS (1) IS2011B (hu)
MY (1) MY121548A (hu)
NO (1) NO313268B1 (hu)
NZ (1) NZ335013A (hu)
OA (1) OA10473A (hu)
PL (2) PL189288B1 (hu)
PT (1) PT781136E (hu)
RO (1) RO118748B1 (hu)
RU (1) RU2168995C2 (hu)
SI (1) SI0781136T1 (hu)
SK (1) SK284564B6 (hu)
WO (1) WO1996007413A1 (hu)
ZA (1) ZA957483B (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
AU9016998A (en) 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
DK1058686T3 (da) 1998-02-25 2007-03-05 Univ Emory 2'-fluornukleosider
DE60042921D1 (de) * 1999-03-29 2009-10-22 Shire Canada Inc Verwendung von cytidinderivaten zur behandlung von leukämie
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
ES2218216T3 (es) 1999-09-24 2004-11-16 Shire Biochem Inc. Analogos de nucleosidos de dioxolano para el tratamiento o la prevencion de infecciones viricas.
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1600451A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-l-nucleosides
AU2002212015B2 (en) * 2000-10-13 2007-01-25 Shire Canada Inc. Dioxolane analogs for improved inter-cellular delivery
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
EP1372658A2 (en) * 2001-03-30 2004-01-02 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
JP2005512984A (ja) * 2001-11-02 2005-05-12 シャイアー バイオケム インコーポレイテッド ジオキソランヌクレオシド類似体を含む白血病の治療のための医薬組成物
RU2302861C3 (ru) * 2001-11-19 2017-04-14 Медигене Аг Лекарственное средство для лечения вирусных кожных и опухолевых заболеваний
KR100631243B1 (ko) 2002-06-21 2006-10-02 엘지전자 주식회사 비디오 데이터의 재생을 관리하기 위한 데이터 구조를갖는 기록 매체
KR100582957B1 (ko) 2002-06-21 2006-05-23 엘지전자 주식회사 비디오 데이터의 재생을 관리하기 위한 데이터 구조를 갖는기록 매체
BR0305211A (pt) 2002-06-24 2005-06-28 Lg Electronics Inc Meio de gravação possuindo estrutura de dados para gerenciamento de reprodução de dados de vìdeo de trajetória de reprodução múltipla gravados no mesmo e aparelhos e métodos de gravação e reprodução
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
EP1518240B1 (en) 2002-06-28 2014-05-07 LG Electronics, Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
CA2469176C (en) 2002-10-14 2010-09-14 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple audio streams recorded thereon and recording and reproducing methods and apparatuses
KR100672111B1 (ko) 2002-10-15 2007-01-19 엘지전자 주식회사 기록된 복수의 그래픽 스트림의 재생을 관리하기 위한데이터 구조를 갖는 기록 매체, 그에 따른 기록 및 재생방법 및 장치
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
EP1604356A4 (en) 2003-02-28 2009-12-16 Lg Electronics Inc RECORD MEDIUM WITH A DATA STRUCTURE FOR MANAGING THE RANDOM / SHUFFLE PLAYBACK OF RECORDED VIDEO DATA, AND METHOD AND DEVICES FOR RECORDING AND PLAYING
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
AR045865A1 (es) 2003-10-09 2005-11-16 Medigene Ag El uso de un polifenol para el tratamiento de una lesion cancerosa o pre-cancerosa de la piel
CN103735560A (zh) * 2005-06-07 2014-04-23 耶鲁大学 使用克来夫定和替比夫定治疗癌症和其它病症或疾病状态的方法
CN101511375B (zh) * 2005-12-02 2012-09-05 耶鲁大学 L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CA3045228C (en) * 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
PT82580B (pt) * 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (hu) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
DE3850571T2 (de) * 1987-03-24 1994-10-27 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate.
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
DE10299039I1 (de) * 1988-12-19 2003-02-20 Wellcome Found Antivirale Pyrimidin- und Purinverbindungen Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Praeparte
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DK0574487T3 (da) * 1991-03-06 2002-10-14 Univ Emory Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995018137A1 (en) * 1993-12-30 1995-07-06 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
MY121548A (en) 2006-02-28
AU704977B2 (en) 1999-05-13
NO971015L (no) 1997-03-05
KR100374477B1 (ko) 2003-06-19
OA10473A (en) 2002-04-08
PL188359B1 (pl) 2005-01-31
CZ63397A3 (en) 1997-07-16
NO971015D0 (no) 1997-03-05
IS4434A (is) 1997-03-04
IS2011B (is) 2005-05-13
FI970918A (fi) 1997-05-02
CN1251680C (zh) 2006-04-19
US8076347B2 (en) 2011-12-13
ES2219666T3 (es) 2004-12-01
SK28197A3 (en) 1997-09-10
DK0781136T3 (da) 2004-08-02
JP3979662B2 (ja) 2007-09-19
DE69533066T2 (de) 2005-06-02
CA2199117A1 (en) 1996-03-14
CN1160351A (zh) 1997-09-24
CA2199117C (en) 2006-04-11
NO313268B1 (no) 2002-09-09
RU2168995C2 (ru) 2001-06-20
IL115156A0 (en) 1995-12-31
US20080171758A1 (en) 2008-07-17
NZ335013A (en) 2000-07-28
AU3586295A (en) 1996-03-27
CN1448142A (zh) 2003-10-15
CZ297873B6 (cs) 2007-04-18
PL318971A1 (en) 1997-07-21
SK284564B6 (sk) 2005-06-02
CN1827108A (zh) 2006-09-06
HUT77172A (hu) 1998-03-02
AP9700939A0 (en) 1997-04-30
US20050261320A1 (en) 2005-11-24
BG101284A (en) 1998-03-31
US7262213B2 (en) 2007-08-28
FI970918A0 (fi) 1997-03-04
EP0781136A4 (en) 1999-06-23
WO1996007413A1 (en) 1996-03-14
BR9508886A (pt) 1997-12-30
PT781136E (pt) 2004-09-30
ZA957483B (en) 1997-06-06
RO118748B1 (ro) 2003-10-30
US6063787A (en) 2000-05-16
KR970705393A (ko) 1997-10-09
AP783A (en) 1999-11-17
DE69533066D1 (de) 2004-06-24
SI0781136T1 (en) 2004-08-31
EP1468687A1 (en) 2004-10-20
EP0781136A1 (en) 1997-07-02
CN1111409C (zh) 2003-06-18
PL189288B1 (pl) 2005-07-29
ATE267015T1 (de) 2004-06-15
EP0781136B1 (en) 2004-05-19
JPH10506385A (ja) 1998-06-23
BG63122B1 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
IL115156A (en) Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
HUP9902455A3 (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
HK1028769A1 (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
HK1053787A1 (zh) 含有hiv蛋白酶抑制劑的藥物組合物
ITVR940019A0 (it) Attrezzo ortopedico, particolarmente per la correzione graduale ester-na di fratture.
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
HUP9802629A3 (en) Use of 1,3-bis(1,2,4-triazolyl)propan-2-ol derivatives for the manufacture of pharmaceutical compositions treating cancers
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
HUP0201187A2 (en) Use of ecteinascidin743 for producing pharmaceutical compositions suitable for treating cancer
HUP9901326A3 (en) Benzopyran derivatives having leukotriene-antagonistic action, pharmaceutical compositions containing these compounds, process for the preparation and use of these compounds and compositions
ZA9710272B (en) Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds.
HUP9802634A3 (en) Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia
HUP0101482A3 (en) Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
FI964212A (fi) Röntgenvarjoainekoostumuksia, jotka sisältävät farmaseuttisesti hyväksyttäviä savia
HUP9901680A3 (en) Use of piperazin-, piperidin- or hexahidropiridazin derivatives for the preparation of pharmaceutical compositions, new piperazin derivatives and pharmaceutical compositions containing these compounds
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
ZA97872B (en) Use of pyrolidine derivatives for the manufacture of medicaments.
IL139531A0 (en) Human antithrombin iii, methods for the production thereof and pharmaceutical compositions containing the same
AU686084B3 (en) Pharmaceutical compositions for the treatment of depressive disorders
AU5245600A (en) Medicinal compositions for treating lower uropathy
ZA991786B (en) Therapeutic treatment for asthma.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired